Abbott Laboratories (ABT)

As the Q3 2025 earnings season unfolds, corporate America is delivering a powerful narrative of resilience and growth, significantly influencing overall stock market movements. Despite a complex backdrop of economic uncertainties and geopolitical tensions, stronger-than-expected corporate performances are largely driving a prevailing sense of optimism among investors. This robust earnings

Abbott eyes 10% EPS growth in 2026 with CGM momentum, new nutrition contracts, and medical device launches driving global expansion.

Investors should be able to count on these stocks to deliver steady and growing income over the long term.

Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 6.9% year on year to $11.37 billion. Its non-GAAP profit of $1.30 per share was in line with analysts’ consensus estimates.

The U.S. stock market closed with a mixed performance recently, reflecting a complex and dynamic environment where investor sentiment is being pulled in multiple directions. As of October 15, 2025, a critical "tug of war" is underway, with strong corporate earnings and the anticipation of Federal Reserve interest rate

Shares of healthcare product and device company Abbott Laboratories (NYSE:ABT) fell 3.5% in the afternoon session after the company reported third-quarter financial results that met, but did not exceed, Wall Street's expectations. 

In a year marked by evolving market dynamics and a persistent search for both growth and stability, two distinct titans of industry—Meta Platforms (NASDAQ: META) and Johnson & Johnson (NYSE: JNJ)—have emerged as standout performers for dividend-seeking investors. As of October 15, 2025, these companies represent compelling examples of

Wall Street rose on Wednesday, with investor optimism lifted by strong bank and corporate earnings alongside growing expectations for further Federal Reserve rate cuts — keeping trade concerns sidelined for now.

Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session.

This is about as safe as a dividend can be.

Wondering which stocks are making significant price gaps? Explore the S&P500 index on Wednesday to find the gap up and gap down stocks in today's session.

Abbott stock fell as Q3 sales missed estimates and 2025 earnings guidance was narrowed despite solid growth in medical devices.

Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 6.9% year on year to $11.37 billion. Its non-GAAP profit of $1.30 per share was in line with analysts’ consensus estimates.

Notably, the company reaffirmed its sales guidance and the midpoint of its earnings outlook.

Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top S&P500 gainers and losers in today's pre-market session.

Abbott Labs Q3 2025 results met EPS views, but trimmed full-year guidance. Sales grew 6.9% as the healthcare giant navigates a complex market.

U.S. stock futures advanced on Wednesday following Tuesday’s mixed close. Futures of major benchmark indices were higher.

Dow Jones gains, but trade tensions limit enthusiasm. Wells Fargo, Citi, JPMorgan, and Goldman Sachs beat expectations.

US stock futures higher, BAC, PZZA, MS expected to report earnings, ASML reports better-than-expected bookings, ABT to report earnings.

Healthcare product and device company Abbott Laboratories (NYSE:ABT) will be reporting earnings this Wednesday morning. Here’s what investors should know.